Back to Authors

Hendzel, Michael J.

https://orcid.org/0000-0002-9603-7945

Mayo Clinic

University of Alberta

Citations 2

ZNF432 stimulates PARylation and inhibits DNA resection to balance PARPi sensitivity and resistance
O’Sullivan, Julia , Kothari, Charu , Caron, Marie‐Christine, Nonfoux, Louis , Beneyton, Adèle , Coulombe, Yan, Thomas, Mélissa , Atalay, Nurgül, Meng, X. Wei, Milano, Larissa , Jean, Dominique , Boisvert, François‐Michel , Hendzel, Michael J. , Milano, Larissa , Kaufmann, Scott H , Hendzel, Michael J , Masson, Jean Yves , Gagné, Jean‐Philippe , Jin, Zhigang , Kaufmann, Scott H. , Masson, Jean‐Yves , Poirier, Guy G.

Nucleic Acids Research | October 12, 2023 | Volume: 51 | Issue: 20 | Pages: 11056-11079

10.1093/nar/gkad791 Get It

Abstract Zinc finger (ZNF) motifs are some of the most frequently occurring domains in the human genome. It was only recently that ZNF proteins emerged as key regulators of genome integrity in mammalian cells. In this study, we report a new role for the Krüppel-type ZNF-containing protein ZNF432 as a novel poly(ADP-ribose) (PAR) reader that regulates the DNA damage response. We show that ZNF432 is recruited to DNA lesions via DNA- and PAR-dependent mechanisms. Remarkably, ZNF432 stimulates PARP-1 activity in vitro and in cellulo. Knockdown of ZNF432 inhibits phospho-DNA-PKcs and increases RAD51 foci formation following irradiation. Moreover, purified ZNF432 preferentially binds single-stranded DNA and impairs EXO1-mediated DNA resection. Consequently, the loss of ZNF432 in a cellular system leads to resistance to PARP inhibitors while its overexpression results in sensitivity. Taken together, our results support the emerging concept that ZNF-containing proteins can modulate PARylation, which can be embodied by the pivotal role of ZNF432 to finely balance the outcome of PARPi response by regulating homologous recombination.
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients
Keats, Jonathan J. , Maxwell, Christopher A. , Hendzel, Michael J. , Chesi, Marta , Bergsagel, P. Leif , Larratt, Loree, Mant, Michael J., Reiman, Tony , Belch, Andrew R. , Pilarski, Linda M., Taylor, Brian J. , Bergsagel, P. Leif , Keats, Jonathan J , Hendzel, Michael J

Blood | January 28, 2005 | Volume: 105 | Issue: 10 | Pages: 4060-4069

10.1182/blood-2004-09-3704 Get It

AbstractMultiple myeloma (MM) is a B-lineage malignancy characterized by diverse genetic subtypes and clinical outcomes. The recurrent immunoglobulin heavy chain (IgH) switch translocation, t(4;14)(p16;q32), is associated with poor outcome, though the mechanism is unclear. Quantitative reverse-transcription–polymerase chain reaction (RT-PCR) for proposed target genes on a panel of myeloma cell lines and purified plasma cells showed that only transcripts originating from the WHSC1/MMSET/NSD2 gene are uniformly dysregulated in all t(4;14)POS patients. The different transcripts detected, multiple myeloma SET domain containing protein (MMSET I), MMSET II, Exon 4a/MMSET III, and response element II binding protein (RE-IIBP), are produced by alternative splicing and alternative transcription initiation events. Translation of the various transcripts, including those from major breakpoint region 4-2 (MB4-2) and MB4-3 breakpoint variants, was confirmed by transient transfection and immunoblotting. Green fluorescent protein (GFP)–tagged MMSET I and II, corresponding to proteins expressed in MB4-1 patients, localized to the nucleus but not nucleoli, whereas the MB4-2 and MB4-3 proteins concentrate in nucleoli. Cloning and localization of the Exon 4a/MMSET III splice variant, which contains the protein segment lost in the MB4-2 variant, identified a novel protein domain that prevents nucleolar localization. Kinetic studies using photobleaching suggest that the breakpoint variants are functionally distinct from wild-type proteins. In contrast, RE-IIBP is universally dysregulated and also potentially functional in all t(4;14)POS patients irrespective of fibroblast growth factor receptor 3 (FGFR3) expression or breakpoint type.